 |
|
|
| |
55th Annual Meeting of the American Association for the Study of Liver Diseases
October 29-November 2, 2004
Boston, MA |
| |
| |
- Pegasys/RBV Improves Fibrosis in Responders, relapsers & Nonresponders with Advanced Fibrosis - (12/06/04)
- Entecavir Resistance - (11/16/04)
- Pegasys/RBV 16 vs 24 Weeks for Genotype 2 & 3 - (11/15/04)
- LB80380, new HBV Drug - (11/15/04)
- Peg-IFN Maintenance Therapy Study: interim analysis at 2 yrs shows positive results - (11/15/04)
- Adefovir + FTC for HBV in HBeAG+: combination therapy for HBV - (11/12/04)
- Prolonged Pegasys+RBV Therapy to 72 Weeks May Improve SVR in Patients Who were HCV RNA+ after 4 weeks & slow responders - (11/10/04)
- PegIFN for HBV, HDV, & HCV - (11/10/04)
- ADEFOVIR FOR HBV- 144 WEEK FOLLOW-UP - (11/10/04)
- HCV & HIV Prevalence in NYC Drug Rehab Facility - (11/09/04)
- Pilot Study, Hi-Dose Pegasys Induction- 37% SVR for IFN/RBV Nonresponders - (11/09/04)
- Durability of SVR, 5 Year follow-up Pegasys plus Copegus - (11/09/04)
- CLINICAL PHARMACOKINETICS OF TELBIVUDINE, A POTENT ANTIVIRAL FOR HEPATITIS B, IN SUBJECTS WITH IMPAIRED HEPATIC OR RENAL FUNCTION - (11/09/04)
- LdT & HBV Therapy Viral Dynamics - (11/09/04)
- LdC, new HBV Drug: 4-week Dosing, Safety & Antiviral Efficacy Study - (11/08/04)
- Remofovir, new HBV drug: prodrug of PMEA - (11/08/04)
- Clevudine, new HBV drug, 3 studies - (11/08/04)
- FTC for HBV - (11/08/04)
- LdT, new HBV Drug: week 52 phase II results; Viral Dynamics - (11/08/04)
- In Vitro Cross-Resistance HBV Drugs - (11/08/04)
- Pegasys+Lamivudine, Pegasys, or Lamivudine for HBV Therapy - (11/05/04)
- Body Changes, Diabetes, Fatty Liver & HIV & HCV - (11/05/04)
- Entecavir in Lamivduine Experienced Patients - (11/05/04)
- Nonresponders in Apricot Achieve Histologic Response, Improve Liver - (11/05/04)
- NEW HCV PROTEASE INHIBITOR STARTS FIRST 14-DAY HUMAN STUDY IN NOVEMBER - (11/04/04)
- Consensus Interferon for Peg/RBV Nonresponders - (11/02/04)
- Entecavir: new HBV drug, phase III study in nucleoside-naïve HBeAg-negative patients - (11/02/04)
- New HCV Drug NM283 + Peginterferon Study - (11/02/04)
- Viramidine, substitute for ribavirin: end-of-treatment response in therapy-naïve patients - (11/01/04)
- Entecavir: new hepatitis B drug-phase III study results of 48-weeks therapy in HBeAg+ nucleoside-naïve patients - (11/01/04)
- Report 1 on Hepatitis B at the Liver Conference AASLD - (11/01/04)
|
|
| |
|
|
|
|
|
|
